Sun Pharma Q1 net profit jumps 40% to Rs 2,836 crore in Q1FY25

Sun Pharma reported a 40% year-on-year (YoY) jump in net profit to Rs 2,836 crore in Q1FY25 led by higher sales growth in domestic formulation, emerging markets and global specialty portfolio.

The company reported net profit of Rs 2,023 crore during the corresponding quarter of the previous year.

Revenue rose 6.3% YoY to Rs. 12,525 crore in Q1FY25.


The earnings for interest, tax, depreciation and amortisation (EBITDA) rose 8.3% to Rs. 3,608 crore in Q1, and EBITDA margins gained 60 basis points YoY to 28.5%.

India formulation sales rose 16.4% YoY to Rs. 4,144.5 crore in Q1FY25. India accounts for 33.1% of Sun Pharma sales.

Sun Pharma holds 8.6% market share and is ranked number one in the Rs. 2.02 lakh crore Indian pharmaceutical market as per AIOCD AWACS MAT June 2024 report.

In Q4FY24, the company launched 6 new products in the Indian market.

The US formulation sales were 1% lower YoY to 3,889 crore. US formulation sales accounted for 31% of consolidated sales.On quarter-on-quarter (q-o-q) basis, US sales were down close to 2%.

Global specialty sales stood at $266 million, up 14.7% YoY in Q1FY25. On q-o-q specialty sales down around 2%.

While emerging markets formulation sales grew 8.8% YoY to Rs 2370 crore, rest-of-the-world (RoW) formulation sales were down 2.9% YoY to Rs 1581 crore.

R&D expenses rose 17% YoY to Rs 794 crore in Q1FY25.